• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

对比抗-HCV 联合 HCVcAg（Elecsys HCV Duo 免疫分析法）与抗-HCV 快速检测，随后采用 qRT-PCR 分析 HCV RNA 以确定治疗的活动性感染。

Comparison of anti-HCV combined with HCVcAg (Elecsys HCV Duo immunoassay) and anti-HCV rapid test followed by HCV RNA analysis using qRT-PCR to identify active infection for treatment.

机构信息

Center of Excellence in Clinical Virology, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.

Center of Excellence in Osteoarthritis and Musculoskeleton, Faculty of Medicine, King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Chulalongkorn University, Bangkok, Thailand.

出版信息

PLoS One. 2024 Nov 18;19(11):e0313771. doi: 10.1371/journal.pone.0313771. eCollection 2024.

DOI:10.1371/journal.pone.0313771
PMID:39556526
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11573151/
Abstract

Hepatitis C virus (HCV) infection can cause acute and chronic hepatitis, leading to liver cirrhosis and hepatocellular carcinoma. The World Health Organization aims to eliminate viral hepatitis by 2030 through extensive screening and treatment. To achieve this goal, comprehensive and widespread screening is essential for diagnosis and treatment. This study aims to evaluate the diagnostic sensitivity and specificity of the Elecsys® HCV Duo immunoassay (Duo-assay), which simultaneously detects anti-HCV antibodies (Duo/anti-HCV) and HCV core antigen (Duo/HCVcAg) in a single sample, compared with initially antibody testing followed by quantitative real-time polymerase chain reaction (qRT-PCR). Additionally, this study aimed to evaluate a relationship between Duo/HCVcAg and qRT-PCR assay in different genotypes. A total of 769 plasma samples were tested using the Duo-assay to further evaluate the test's performance and conduct Duo/HCVcAg correlation analysis using qRT-PCR for each genotype. Among the active infection group (anti-HCV+/RNA+; n = 473), the Duo-assay showed 100% sensitivity for detecting Duo/anti-HCV and 70.6% for Duo/HCVcAg. In the resolved infection group (anti-HCV+/RNA-; n = 176), the assay showed 100% sensitivity for Duo/anti-HCV and 100% specificity for Duo/HCVcAg. In the non-infected group (anti-HCV-/RNA-; n = 120), the assay showed 100% specificity for both Duo/anti-HCV and Duo/HCVcAg. Moreover, no correlation was observed between the Duo/HCVcAg and HCV RNA tests, irrespective of genotype. These findings indicate that the Duo-assay is highly sensitive for detecting anti-HCV and specifically identifies patients with active infection. Nevertheless, cases with anti-HCV+/HCVcAg-results should undergo additional confirmation with western blot/immunoblot and qRT-PCR to ensure diagnostic accuracy, especially in Blood donation facilities.

摘要

丙型肝炎病毒（HCV）感染可引起急性和慢性肝炎，导致肝硬化和肝细胞癌。世界卫生组织（WHO）的目标是到 2030 年通过广泛的筛查和治疗消除病毒性肝炎。为了实现这一目标，全面广泛的筛查对于诊断和治疗至关重要。本研究旨在评估 Elecsys® HCV Duo 免疫测定法（Duo-assay）的诊断灵敏度和特异性，该方法可在单个样本中同时检测抗 HCV 抗体（Duo/anti-HCV）和 HCV 核心抗原（Duo/HCVcAg）。与最初的抗体检测后进行定量实时聚合酶链反应（qRT-PCR）相比，该研究还旨在评估 Duo/HCVcAg 与不同基因型的 qRT-PCR 检测之间的关系。共对 769 份血浆样本进行了 Duo-assay 检测，以进一步评估该检测的性能，并对每个基因型进行 Duo/HCVcAg 相关性分析。在活动性感染组（anti-HCV+/RNA+；n=473）中，Duo-assay 检测 Duo/anti-HCV 的灵敏度为 100%，检测 Duo/HCVcAg 的灵敏度为 70.6%。在已解决感染组（anti-HCV+/RNA-；n=176）中，该检测方法对 Duo/anti-HCV 的灵敏度为 100%，对 Duo/HCVcAg 的特异性为 100%。在未感染组（anti-HCV-/RNA-；n=120）中，该检测方法对 Duo/anti-HCV 和 Duo/HCVcAg 的特异性均为 100%。此外，无论基因型如何，Duo/HCVcAg 和 HCV RNA 检测之间均无相关性。这些发现表明，Duo-assay 对检测抗 HCV 非常敏感，并且特异性识别出具有活动性感染的患者。然而，对于出现抗 HCV+/HCVcAg-结果的病例，应使用 Western blot/immunoblot 和 qRT-PCR 进行进一步确认，以确保诊断准确性，特别是在血液采集机构中。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5f39/11573151/c9cceda49d26/pone.0313771.g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5f39/11573151/2783f84832d7/pone.0313771.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5f39/11573151/2f6f36d30455/pone.0313771.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5f39/11573151/6b0c68644206/pone.0313771.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5f39/11573151/c9cceda49d26/pone.0313771.g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5f39/11573151/2783f84832d7/pone.0313771.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5f39/11573151/2f6f36d30455/pone.0313771.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5f39/11573151/6b0c68644206/pone.0313771.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5f39/11573151/c9cceda49d26/pone.0313771.g004.jpg

相似文献

1
Comparison of anti-HCV combined with HCVcAg (Elecsys HCV Duo immunoassay) and anti-HCV rapid test followed by HCV RNA analysis using qRT-PCR to identify active infection for treatment.对比抗-HCV 联合 HCVcAg（Elecsys HCV Duo 免疫分析法）与抗-HCV 快速检测，随后采用 qRT-PCR 分析 HCV RNA 以确定治疗的活动性感染。
PLoS One. 2024 Nov 18;19(11):e0313771. doi: 10.1371/journal.pone.0313771. eCollection 2024.
2
Hepatitis C virus core antigen: A simplified treatment monitoring tool, including for post-treatment relapse.丙型肝炎病毒核心抗原：一种简化的治疗监测工具，包括用于治疗后复发的情况。
J Clin Virol. 2017 Jul;92:32-38. doi: 10.1016/j.jcv.2017.05.007. Epub 2017 May 11.
3
Clinical utility of hepatitis C virus core antigen (HCVcAg) assay to identify active HCV infection in hemodialysis and renal transplant patients.丙型肝炎病毒核心抗原（HCVcAg）检测在血液透析和肾移植患者中识别丙型肝炎病毒活跃感染的临床应用。
PLoS One. 2021 Apr 22;16(4):e0250263. doi: 10.1371/journal.pone.0250263. eCollection 2021.
4
Diagnostic utility of hepatitis C virus core antigen in hemodialysis patients.丙型肝炎病毒核心抗原在血液透析患者中的诊断效用
Clin Biochem. 2008 May;41(7-8):447-52. doi: 10.1016/j.clinbiochem.2007.12.024. Epub 2008 Jan 11.
5
Reliability of hepatitis C virus core antigen assay for detection of viremia in HCV genotypes 1, 2, 3, and 4 infected blood donors: a collaborative study between Japan, Egypt, and Uzbekistan.丙型肝炎病毒核心抗原检测法在检测感染1、2、3和4型丙型肝炎病毒献血者病毒血症中的可靠性：日本、埃及和乌兹别克斯坦的一项合作研究。
J Med Virol. 2004 Jun;73(2):216-22. doi: 10.1002/jmv.20078.
6
Hepatitis C virus core antigen: A diagnostic and treatment monitoring marker of hepatitis C virus in Indian population.丙型肝炎病毒核心抗原：印度人群丙型肝炎病毒的诊断和治疗监测标志物。
Indian J Gastroenterol. 2024 Aug;43(4):799-804. doi: 10.1007/s12664-024-01549-7. Epub 2024 Apr 15.
7
Comparison of a dual antibody and antigen HCV immunoassay to standard of care algorithmic testing.比较双重抗体和抗原 HCV 免疫测定与标准护理算法检测。
J Clin Microbiol. 2024 Oct 16;62(10):e0083224. doi: 10.1128/jcm.00832-24. Epub 2024 Sep 16.
8
[Detection of hepatitis C virus antigen in hemodialysis patients].[血液透析患者丙型肝炎病毒抗原的检测]
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. 2009 Jun;23(3):232-4.
9
Clinical utility of HCV core antigen detection and quantification using serum samples and dried blood spots in people who inject drugs in Dar-es-Salaam, Tanzania.坦桑尼亚达累斯萨拉姆注射吸毒人群中使用血清样本和干血斑检测和定量 HCV 核心抗原的临床实用性。
J Int AIDS Soc. 2017 Sep 19;20(1):21856. doi: 10.7448/IAS.20.1.21856.
10
Hepatitis C virus core antigen is cost-effective in community-based screening of active hepatitis C infection in Taiwan.在台湾，基于社区的丙型肝炎病毒核心抗原筛查活动感染具有成本效益。
J Formos Med Assoc. 2020 Jan;119(1 Pt 3):504-508. doi: 10.1016/j.jfma.2019.07.011. Epub 2019 Jul 23.

引用本文的文献

1
Acceleration of Diagnosis and Treatment Initiation Using the Elecsys® HCV Duo Assay.使用Elecsys® HCV Duo检测法加速诊断及治疗启动
Cureus. 2025 Jul 1;17(7):e87145. doi: 10.7759/cureus.87145. eCollection 2025 Jul.
2
A comparative national survey on the gradual decline of hepatitis C virus prevalence in Thailand, 2004, 2014, and 2024.一项关于2004年、2014年和2024年泰国丙型肝炎病毒流行率逐渐下降的全国性比较调查。
Sci Rep. 2025 Jun 5;15(1):19794. doi: 10.1038/s41598-025-04578-0.
3
Hepatitis C Virus-Core Antigen: Implications in Diagnostic, Treatment Monitoring and Clinical Outcomes.

本文引用的文献

1
Progress towards elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission update.消除病毒性肝炎的进展：《柳叶刀·胃肠病学和肝病学》委员会最新报告
Lancet Gastroenterol Hepatol. 2024 Apr;9(4):346-365. doi: 10.1016/S2468-1253(23)00321-7. Epub 2024 Feb 15.
2
WHO hepatitis C elimination targets: the global equity challenge.世界卫生组织丙型肝炎消除目标：全球公平挑战
Lancet Gastroenterol Hepatol. 2024 Apr;9(4):286-288. doi: 10.1016/S2468-1253(23)00408-9. Epub 2024 Feb 15.
3
Simplified Test-to-Treat Strategy for Hepatitis C in Thailand: The Phetchabun Model.
丙型肝炎病毒核心抗原：在诊断、治疗监测及临床结局中的意义
Viruses. 2024 Nov 29;16(12):1863. doi: 10.3390/v16121863.
泰国简化丙型肝炎的检测-治疗策略：碧差汶模式。
J Infect Dis. 2023 Sep 13;228(Suppl 3):S198-S203. doi: 10.1093/infdis/jiac490.
4
An amino acid substitution in HCV core antigen limits its use as a reliable measure of HCV infection compared with HCV RNA.与 HCV RNA 相比，丙型肝炎病毒核心抗原中的一个氨基酸取代限制了其作为 HCV 感染可靠指标的用途。
PLoS One. 2023 Jun 29;18(6):e0287694. doi: 10.1371/journal.pone.0287694. eCollection 2023.
5
HCV Core-antigen Assay as an Effective Alternative to HCV RNA Quantification in Patients With Hepatitis C.丙型肝炎病毒核心抗原检测作为丙型肝炎患者 HCV RNA 定量检测的有效替代方法。
In Vivo. 2023 Jul-Aug;37(4):1498-1503. doi: 10.21873/invivo.13234.
6
Qualitative hepatitis C virus RNA assay identifies active infection with sufficient viral load for treatment among Phetchabun residents in Thailand.定性丙型肝炎病毒 RNA 检测鉴定出泰国巴吞府居民具有足够治疗病毒载量的活跃感染。
PLoS One. 2023 Jan 19;18(1):e0268728. doi: 10.1371/journal.pone.0268728. eCollection 2023.
7
Multicenter performance evaluation of the Elecsys HCV Duo immunoassay.Elecsys HCV Duo免疫测定法的多中心性能评估
J Clin Virol. 2022 Nov;156:105293. doi: 10.1016/j.jcv.2022.105293. Epub 2022 Sep 5.
8
Breakthroughs in hepatitis C research: from discovery to cure.丙型肝炎研究的突破：从发现到治愈。
Nat Rev Gastroenterol Hepatol. 2022 Aug;19(8):533-550. doi: 10.1038/s41575-022-00608-8. Epub 2022 May 20.
9
Long-term persistence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein-specific and neutralizing antibodies in recovered COVID-19 patients.康复的 COVID-19 患者中严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）刺突蛋白特异性和中和抗体的长期持久性。
PLoS One. 2022 Apr 21;17(4):e0267102. doi: 10.1371/journal.pone.0267102. eCollection 2022.
10
Prescreening with a Rapid Diagnostic Test Followed by a Confirmatory Qualitative Nucleic Acid Test Can Simplify Hepatitis C Diagnosis.采用快速诊断检测进行预筛查，随后进行定性核酸确证检测可简化丙型肝炎诊断。
Am J Trop Med Hyg. 2022 Feb 28;106(5):1534-8. doi: 10.4269/ajtmh.21-1016.